Radiotherapy plus cetuximab for locoregionally advanced squamous cell carcinoma of the head and neck
Adding the EGFR antibody cetuximab to radiotherapy lengthened survival in locally advanced head and neck cancer by about 20 months without increasing the mucosal toxicity of radiotherapy, giving patients unfit for cisplatin an alternative.
Overview
Phase 3 trial of 424 patients with stage III to IV squamous cell carcinoma of the oropharynx, hypopharynx or larynx randomised to high-dose radiotherapy alone or with weekly cetuximab.
Median overall survival was 49.0 versus 29.3 months (hazard ratio 0.74) and locoregional control 24.4 versus 14.9 months; apart from acneiform rash and infusion reactions, toxicity was not increased. Later analyses suggested the benefit was concentrated in oropharyngeal cancer.
- Median overall survival 49.0 vs 29.3 months; hazard ratio 0.74.
- Median locoregional control 24.4 vs 14.9 months.
Cetuximab-radiotherapy is the standard for patients who cannot receive cisplatin; head-to-head trials in HPV-positive disease (RTOG 1016, De-ESCALaTE) later showed it inferior to cisplatin where cisplatin is possible.
- Never compared directly with cisplatin chemoradiation in this trial.
- HPV status was not known.
Similar pages
not linked directly; found by shared links- TrialBonner trial (cetuximab plus radiotherapy)
Shares Hypopharyngeal cancer, HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), Cetuximab.
- Key paperEORTC 22931: postoperative irradiation with or without concomitant cisplatin for locally advanced head and neck cancer
Shares Lip cancer, HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), New England Journal of Medicine.
- Key paperKEYNOTE-689: neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck cancer
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), New England Journal of Medicine.
- Key paperPD-1 blockade with cemiplimab in advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1)
- Key paperHuman papillomavirus and survival of patients with oropharyngeal cancer (RTOG 0129)
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), New England Journal of Medicine.
- Key paperRTOG 9501: postoperative concurrent radiotherapy and chemotherapy for high-risk head and neck squamous cell carcinoma
Shares HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer), New England Journal of Medicine.
- Key paperKRYSTAL-1: adagrasib with or without cetuximab in KRAS G12C-mutated colorectal cancer
Shares Cetuximab, New England Journal of Medicine.
- Key paperEXTREME: platinum-based chemotherapy plus cetuximab in recurrent or metastatic head and neck cancer
Shares Cetuximab, New England Journal of Medicine.